Moreover, it has been observed that PPAR gamma agonists generated short-term favorable effects in patients with early AD and mild cognitive impairment, because they might regulate in-vitro processing of the amyloid precursor protein, which plays a central role in the pathophysiology of AD [26]. The gene discussed is APP; the disease is Alzheimer disease.